HomeMarketsBondsJNJ, LLY, PFE: The Hype Around GLP-1 Drugs

JNJ, LLY, PFE: The Hype Around GLP-1 Drugs

Johnson & Johnson (JNJ) delivered a strong quarter and tight expense control was evident as SG&A and R&D both grew below expectations, notes Lee Brown. He discusses health care trends to watch and names in the health care sector to watch including JNJ, LLY, NVO, and PFE. He talks about how JNJ’s innovative medicines segment delivered a strong performance primarily driven by its immunology franchise. He examines the hype around GLP-1 drugs and Daiichi Sankyo and Merck’s $22B commercialization deal. Tune in to find out more about the stock market today.

The Watch List

20 Oct 2023

SHARE

ON AIR
8:00 pm
Next Gen Investing
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Liz Ann Live
REPLAY
1:30 pm
The Wrap
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
ON AIR
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor